Email Page Print Page

Corporate Governance *



BDSI® Code of Ethical Conduct

On March 24, 2003, BDSI®'s Board of Directors adopted the Code of Ethical Conduct for the company's principal executive and financial officers. (revision: April 2014)


BDSI® Disclosure Policy

BioDelivery Sciences International, Inc. is committed to the fair disclosure of information about the company consistent with the Securities and Exchange Commission's Regulation Fair Disclosure ("Regulation FD").


Audit Committee Charter - Amended July 2014


Nominating and Corporate Governance Committee Charter - Adopted May 19, 2004 


Compensation Committee Charter - Amended July 2014


Lead Director Charter - Adopted July 26, 2007



* Each of our Board committees reviews its charter for potential updates on an annual basis.  In addition, our Board of Directors reviews our company's Code of Ethical Conduct for potential updates on an annual basis.

Get the latest details on our products and services.

Top News

BioDelivery Sciences Announces BEMA Buprenorphine NDA Submission on Track following Pre-NDA Meeting with FDA
BEMA Buprenorphine on track for late 2014 or early 2015 NDA filing by partner Endo Pharmaceuticals

BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2014 Financials
BUNAVAILâ„¢ (buprenorphine and naloxone) buccal film (CIII) approved by FDA for the maintenance treatment of opioid dependence; US launch planned for late Q3